Regrettably the original version of the above article contained errors in Table 2 and wrong values in the text. The corrected table is presented here and the values which have been corrected now appear in bold text. Page 1223 abstract Global MBF showed an increase from 180.2 ± 59.9 to 193.6 ± 60.8 mL minute/100 g (P = .002) after beta blocker withdrawal. Page 1225 Mean systolic and mean diastolic blood pressure during adenosine were nearly identical (P = .77 and P = .79) with and without beta blocker. Mean heart rate and mean RPP during adenosine significantly increased after beta blocker withdrawal by 15.2% ± 17% (P = .001) and 16.2% ± 23% (P = .004), respectively. Page 1226 The data are listed in Table 2, lower third. Global MBF showed a significant increase by 7.4% ± 10% (P = .002) after beta blocker withdrawal. The individual data are depicted in Figure 1. All but three patients had a lower global MBF without beta blocker than with. The segmental MBF values (Figure 2) demonstrated a strong correlation over the entire range of perfusion values. The average effect was a slight perfusion shift of about 1015 mL minute-1/100 g in the range of 100-300 mL minute-1/100 g. The mCR under adenosine declined by 8.1% ± 11% (P = .038) and the normalized RPP by 16.2% ± 21% (P = .004) after betablocker discontinuation. Table 2 Hemodynamic response under adenosine, perfusion, and left-ventricular function.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828149 | PMC |
http://dx.doi.org/10.1007/s12350-019-01593-3 | DOI Listing |
Introduction: The infarcted heart is energetically compromised exhibiting a deficient production of adenosine triphosphate (ATP) and the ensuing impaired contractile function. Short-term blockade of the protein S100A9 improves cardiac performance in mice after myocardial infarction (MI). The implications upon ATP production during this process are not known.
View Article and Find Full Text PDFCureus
December 2024
Neuroscience, Barking, Havering and Redbridge University Hospitals NHS Trust, London, GBR.
Stroke remains a leading cause of death globally, with survivors facing both physical and psychological challenges. While acute stroke treatment has improved, many patients develop post-stroke anxiety (PSA), particularly generalized anxiety disorder. PSA represents a significant clinical challenge as most stroke survivors suffer from it.
View Article and Find Full Text PDFCureus
December 2024
Pediatric Cardiology, Centro Hospitalar Lisboa Central, Unidade Local de Saúde de São José, Lisbon, PRT.
Long QT Syndrome (LQTS) is a rare hereditary canalopathy, characterized by prolonged ventricular repolarization, which can lead to malignant tachyarrhythmias at a young age. Treatment typically involves healthy lifestyle changes and β-blocker therapy. In specific cases, the implantation of an implantable cardioverter defibrillator (ICD) can be an option.
View Article and Find Full Text PDFJ Vasc Anom (Phila)
September 2024
Vascular Biology Program, Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.
Objectives: Infantile hemangioma (IH) is a benign vascular tumor that occurs in 5% of infants, predominantly in female and preterm neonates. Propranolol is the mainstay of treatment for IH. Given the short half-life of propranolol regarding β-adrenergic receptor inhibition as well as its side effects, propranolol is administered to infants 2-3 times daily with 1 mg/kg/dose.
View Article and Find Full Text PDFRecent Adv Inflamm Allergy Drug Discov
January 2025
Department of Internal Medicine, Clinical Research Center, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Background: Timolol is a beta-adrenergic blocker that has been shown to be effective in the healing of wounds. Oral mucositis (OM), an acute inflammation of the oral mucosa, is a bothersome side effect of some regimens of chemotherapy in which the oral mucosa becomes ulcerated. The current study aimed to evaluate the prophylactic effects of timolol mouthwash in preventing OM in adult patients receiving chemotherapy compared to the placebo.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!